Concepts (242)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| HIV Protease | 13 | 2019 | 86 | 7.80 | Why? |
| HIV Protease Inhibitors | 13 | 2019 | 434 | 6.97 | Why? |
| HIV-1 | 14 | 2019 | 3365 | 3.12 | Why? |
| Drug Design | 9 | 2019 | 2627 | 2.38 | Why? |
| Crystallography, X-Ray | 12 | 2019 | 2689 | 1.54 | Why? |
| Furans | 4 | 2018 | 156 | 1.48 | Why? |
| HIV Reverse Transcriptase | 2 | 2019 | 104 | 1.44 | Why? |
| Hepatitis B virus | 6 | 2019 | 882 | 1.19 | Why? |
| Ligands | 8 | 2019 | 1300 | 0.98 | Why? |
| Boronic Acids | 2 | 2019 | 30 | 0.95 | Why? |
| Carboxylic Acids | 1 | 2019 | 24 | 0.83 | Why? |
| Luminescent Proteins | 2 | 2017 | 142 | 0.82 | Why? |
| Guanine | 2 | 2018 | 146 | 0.82 | Why? |
| Ethers, Cyclic | 1 | 2019 | 12 | 0.82 | Why? |
| Quinine | 1 | 2019 | 56 | 0.79 | Why? |
| Chromans | 1 | 2018 | 8 | 0.78 | Why? |
| Naphthalenes | 1 | 2018 | 94 | 0.73 | Why? |
| Structure-Activity Relationship | 7 | 2019 | 2219 | 0.69 | Why? |
| Macrocyclic Compounds | 1 | 2017 | 78 | 0.68 | Why? |
| Carbamates | 2 | 2018 | 485 | 0.68 | Why? |
| Darunavir | 2 | 2018 | 477 | 0.68 | Why? |
| Phthalic Acids | 1 | 2017 | 40 | 0.67 | Why? |
| Reverse Transcriptase Inhibitors | 1 | 2019 | 309 | 0.66 | Why? |
| Raltegravir Potassium | 1 | 2017 | 132 | 0.65 | Why? |
| HIV Integrase | 1 | 2016 | 67 | 0.63 | Why? |
| Cytological Techniques | 1 | 2016 | 79 | 0.61 | Why? |
| Anti-HIV Agents | 2 | 2019 | 2209 | 0.60 | Why? |
| Mucin-1 | 2 | 2018 | 277 | 0.59 | Why? |
| Indoles | 2 | 2021 | 1243 | 0.58 | Why? |
| Optical Imaging | 1 | 2016 | 197 | 0.56 | Why? |
| HIV Integrase Inhibitors | 1 | 2016 | 173 | 0.56 | Why? |
| Protein Multimerization | 2 | 2021 | 1336 | 0.56 | Why? |
| Multiple Myeloma | 4 | 2019 | 1064 | 0.55 | Why? |
| Post-Exposure Prophylaxis | 1 | 2017 | 472 | 0.49 | Why? |
| Models, Molecular | 8 | 2020 | 7616 | 0.49 | Why? |
| Mutation, Missense | 1 | 2018 | 863 | 0.46 | Why? |
| Leukocytes, Mononuclear | 3 | 2017 | 2115 | 0.43 | Why? |
| Antiviral Agents | 11 | 2021 | 41703 | 0.42 | Why? |
| Molecular Conformation | 3 | 2019 | 374 | 0.39 | Why? |
| Molecular Structure | 3 | 2019 | 1539 | 0.38 | Why? |
| Stereoisomerism | 3 | 2019 | 121 | 0.37 | Why? |
| Drug Resistance, Multiple, Viral | 2 | 2018 | 37 | 0.35 | Why? |
| Janus Kinase 3 | 2 | 2017 | 46 | 0.35 | Why? |
| Mice, Inbred NOD | 2 | 2017 | 134 | 0.34 | Why? |
| Mice, SCID | 2 | 2017 | 225 | 0.33 | Why? |
| Mutant Proteins | 2 | 2019 | 328 | 0.33 | Why? |
| HIV Infections | 5 | 2018 | 11620 | 0.30 | Why? |
| Microbial Sensitivity Tests | 4 | 2019 | 2886 | 0.30 | Why? |
| Genes, Reporter | 2 | 2017 | 472 | 0.30 | Why? |
| Inhibitory Concentration 50 | 2 | 2017 | 907 | 0.28 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 1573 | 0.26 | Why? |
| Rats | 4 | 2018 | 2764 | 0.25 | Why? |
| Protein Conformation | 3 | 2019 | 4386 | 0.25 | Why? |
| Virus Replication | 4 | 2021 | 14331 | 0.23 | Why? |
| Catalytic Domain | 2 | 2019 | 1757 | 0.23 | Why? |
| Binding Sites | 4 | 2019 | 6201 | 0.22 | Why? |
| Protein Structure, Tertiary | 2 | 2017 | 1565 | 0.22 | Why? |
| Drug Resistance, Viral | 2 | 2017 | 1083 | 0.21 | Why? |
| Cell Line | 4 | 2021 | 12040 | 0.21 | Why? |
| Immunoglobulin G | 3 | 2021 | 21571 | 0.21 | Why? |
| Animals | 15 | 2021 | 78931 | 0.21 | Why? |
| Cysteine | 1 | 2021 | 238 | 0.20 | Why? |
| Zidovudine | 1 | 2019 | 63 | 0.20 | Why? |
| Adenosine Triphosphatases | 1 | 2019 | 78 | 0.20 | Why? |
| Dose-Response Relationship, Drug | 2 | 2019 | 3776 | 0.19 | Why? |
| Glutathione | 1 | 2021 | 280 | 0.19 | Why? |
| Inosine | 1 | 2018 | 9 | 0.19 | Why? |
| Ceruloplasmin | 1 | 2018 | 12 | 0.19 | Why? |
| Deoxyguanosine | 1 | 2018 | 19 | 0.19 | Why? |
| Sulfonamides | 2 | 2018 | 1294 | 0.18 | Why? |
| Halogenation | 1 | 2018 | 51 | 0.18 | Why? |
| Iron Metabolism Disorders | 1 | 2018 | 24 | 0.18 | Why? |
| Heptanes | 1 | 2017 | 4 | 0.18 | Why? |
| Ribonuclease H | 1 | 2017 | 4 | 0.18 | Why? |
| Cell Survival | 3 | 2019 | 1581 | 0.18 | Why? |
| Bortezomib | 2 | 2019 | 125 | 0.18 | Why? |
| Serial Passage | 1 | 2017 | 126 | 0.18 | Why? |
| Pyrrolidinones | 1 | 2017 | 66 | 0.17 | Why? |
| Cytidine | 1 | 2019 | 219 | 0.17 | Why? |
| Amino Acid Sequence | 2 | 2020 | 6049 | 0.17 | Why? |
| Pyrans | 1 | 2017 | 56 | 0.17 | Why? |
| Genes, Tumor Suppressor | 1 | 2017 | 43 | 0.17 | Why? |
| Cell Line, Tumor | 4 | 2019 | 3608 | 0.17 | Why? |
| COS Cells | 1 | 2016 | 157 | 0.16 | Why? |
| Benzothiazoles | 1 | 2017 | 128 | 0.16 | Why? |
| Protein Binding | 3 | 2018 | 11430 | 0.16 | Why? |
| Nuclear Proteins | 1 | 2019 | 321 | 0.16 | Why? |
| Pancytopenia | 1 | 2018 | 113 | 0.16 | Why? |
| Endoplasmic Reticulum | 1 | 2019 | 430 | 0.16 | Why? |
| Staining and Labeling | 1 | 2017 | 169 | 0.16 | Why? |
| Disease Models, Animal | 3 | 2020 | 10998 | 0.15 | Why? |
| Atazanavir Sulfate | 1 | 2018 | 213 | 0.15 | Why? |
| Trans-Activators | 1 | 2017 | 170 | 0.15 | Why? |
| Drug Resistance, Neoplasm | 1 | 2019 | 447 | 0.15 | Why? |
| Vero Cells | 3 | 2021 | 14117 | 0.15 | Why? |
| Carcinogenesis | 1 | 2017 | 236 | 0.14 | Why? |
| Pyridines | 1 | 2021 | 680 | 0.14 | Why? |
| Proto-Oncogene Proteins | 1 | 2017 | 340 | 0.14 | Why? |
| Mice | 6 | 2021 | 21357 | 0.13 | Why? |
| Diplopia | 1 | 2014 | 84 | 0.13 | Why? |
| Nitriles | 1 | 2018 | 1053 | 0.13 | Why? |
| Humans | 33 | 2021 | 930598 | 0.12 | Why? |
| Molecular Dynamics Simulation | 2 | 2017 | 4155 | 0.12 | Why? |
| Hydrogen Bonding | 1 | 2014 | 599 | 0.12 | Why? |
| Mice, Knockout | 1 | 2017 | 1815 | 0.12 | Why? |
| Cyclophosphamide | 1 | 2014 | 387 | 0.12 | Why? |
| DNA | 1 | 2018 | 778 | 0.12 | Why? |
| Central Nervous System | 1 | 2017 | 701 | 0.11 | Why? |
| Neurodegenerative Diseases | 1 | 2018 | 469 | 0.11 | Why? |
| Amino Acid Substitution | 1 | 2019 | 1706 | 0.11 | Why? |
| Cysteine Endopeptidases | 1 | 2020 | 1557 | 0.11 | Why? |
| HIV | 1 | 2018 | 1116 | 0.11 | Why? |
| Molecular Docking Simulation | 2 | 2017 | 6902 | 0.11 | Why? |
| Small Molecule Libraries | 1 | 2019 | 1060 | 0.11 | Why? |
| Plasma | 1 | 2021 | 1809 | 0.11 | Why? |
| Blood-Brain Barrier | 1 | 2014 | 531 | 0.10 | Why? |
| Remission Induction | 1 | 2014 | 950 | 0.10 | Why? |
| Genetic Vectors | 1 | 2017 | 1600 | 0.10 | Why? |
| Lymph Nodes | 1 | 2017 | 1060 | 0.10 | Why? |
| Immunohistochemistry | 1 | 2017 | 2275 | 0.10 | Why? |
| DNA Methylation | 2 | 2005 | 688 | 0.10 | Why? |
| Enzyme Inhibitors | 1 | 2019 | 1881 | 0.09 | Why? |
| Xenograft Model Antitumor Assays | 2 | 2019 | 274 | 0.09 | Why? |
| Immunization, Passive | 2 | 2021 | 10067 | 0.09 | Why? |
| Antibodies, Neutralizing | 4 | 2021 | 25288 | 0.08 | Why? |
| Point-of-Care Systems | 1 | 2020 | 2955 | 0.08 | Why? |
| Gene Expression | 1 | 2017 | 3332 | 0.08 | Why? |
| Drug Evaluation, Preclinical | 2 | 2018 | 3347 | 0.08 | Why? |
| Cells, Cultured | 1 | 2017 | 5835 | 0.08 | Why? |
| Kinetics | 1 | 2014 | 3238 | 0.08 | Why? |
| Amides | 1 | 2017 | 1864 | 0.07 | Why? |
| Burkitt Lymphoma | 1 | 2005 | 15 | 0.07 | Why? |
| Gene Expression Regulation, Leukemic | 1 | 2005 | 31 | 0.07 | Why? |
| Chloroquine | 1 | 2020 | 3152 | 0.07 | Why? |
| Mesocricetus | 2 | 2021 | 1847 | 0.07 | Why? |
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2004 | 28 | 0.07 | Why? |
| Leukemia, Myeloid | 1 | 2005 | 76 | 0.07 | Why? |
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2005 | 82 | 0.07 | Why? |
| Receptors, Virus | 1 | 2021 | 5659 | 0.07 | Why? |
| Tumor Suppressor Proteins | 1 | 2005 | 165 | 0.07 | Why? |
| Lopinavir | 1 | 2018 | 4308 | 0.06 | Why? |
| Japan | 3 | 2021 | 6653 | 0.06 | Why? |
| Antigens, Viral | 1 | 2020 | 6298 | 0.06 | Why? |
| Immunoglobulin M | 1 | 2021 | 9091 | 0.06 | Why? |
| Adenosine Monophosphate | 1 | 2021 | 5652 | 0.06 | Why? |
| Alanine | 1 | 2021 | 5687 | 0.06 | Why? |
| Cricetinae | 2 | 2021 | 3344 | 0.06 | Why? |
| Pyrazines | 1 | 2014 | 1783 | 0.06 | Why? |
| Cell Cycle Proteins | 1 | 2005 | 297 | 0.06 | Why? |
| Dexamethasone | 1 | 2014 | 2055 | 0.06 | Why? |
| Viral Nonstructural Proteins | 1 | 2020 | 4810 | 0.06 | Why? |
| Genotype | 1 | 2014 | 4697 | 0.06 | Why? |
| Glutaredoxins | 1 | 2021 | 15 | 0.06 | Why? |
| Survival Rate | 1 | 2017 | 9206 | 0.06 | Why? |
| X-Ray Microtomography | 1 | 2021 | 115 | 0.06 | Why? |
| Cell Proliferation | 2 | 2019 | 1973 | 0.06 | Why? |
| Epidemics | 1 | 2021 | 6407 | 0.05 | Why? |
| Administration, Oral | 2 | 2018 | 2340 | 0.05 | Why? |
| Brain | 1 | 2018 | 5133 | 0.05 | Why? |
| Transcription Factor CHOP | 1 | 2019 | 29 | 0.05 | Why? |
| Dimerization | 1 | 2021 | 475 | 0.05 | Why? |
| S Phase | 1 | 2018 | 12 | 0.05 | Why? |
| Drug Screening Assays, Antitumor | 1 | 2019 | 138 | 0.05 | Why? |
| Ribonucleoproteins | 1 | 2020 | 151 | 0.05 | Why? |
| eIF-2 Kinase | 1 | 2019 | 117 | 0.05 | Why? |
| Immunoenzyme Techniques | 1 | 2021 | 448 | 0.05 | Why? |
| Tokyo | 1 | 2021 | 645 | 0.05 | Why? |
| Cell Cycle Checkpoints | 1 | 2018 | 126 | 0.05 | Why? |
| Intestinal Absorption | 1 | 2018 | 64 | 0.05 | Why? |
| Hep G2 Cells | 1 | 2019 | 391 | 0.05 | Why? |
| Antibodies, Viral | 5 | 2021 | 51949 | 0.04 | Why? |
| Ubiquitination | 1 | 2019 | 343 | 0.04 | Why? |
| Gene Knockdown Techniques | 1 | 2018 | 347 | 0.04 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.04 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.04 | Why? |
| Chemistry Techniques, Synthetic | 1 | 2017 | 60 | 0.04 | Why? |
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2017 | 47 | 0.04 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.04 | Why? |
| Endoplasmic Reticulum Stress | 1 | 2019 | 253 | 0.04 | Why? |
| Biological Availability | 1 | 2018 | 388 | 0.04 | Why? |
| Mutation | 1 | 2017 | 12376 | 0.04 | Why? |
| Ki-67 Antigen | 1 | 2017 | 139 | 0.04 | Why? |
| Viral Load | 1 | 2017 | 15850 | 0.04 | Why? |
| Neoplasm Invasiveness | 1 | 2018 | 582 | 0.04 | Why? |
| Luminescent Measurements | 1 | 2021 | 924 | 0.04 | Why? |
| Seroepidemiologic Studies | 2 | 2021 | 10017 | 0.04 | Why? |
| Rats, Sprague-Dawley | 1 | 2018 | 987 | 0.04 | Why? |
| Endoribonucleases | 1 | 2019 | 407 | 0.04 | Why? |
| Lung | 2 | 2021 | 31049 | 0.03 | Why? |
| Chromatography, Liquid | 1 | 2018 | 640 | 0.03 | Why? |
| Bone Marrow | 1 | 2018 | 492 | 0.03 | Why? |
| Aged | 4 | 2021 | 215776 | 0.03 | Why? |
| Trace Elements | 1 | 2018 | 284 | 0.03 | Why? |
| Female | 7 | 2021 | 380317 | 0.03 | Why? |
| Administration, Intravenous | 1 | 2018 | 1115 | 0.03 | Why? |
| False Negative Reactions | 1 | 2020 | 1785 | 0.03 | Why? |
| Aged, 80 and over | 2 | 2021 | 88759 | 0.03 | Why? |
| Tandem Mass Spectrometry | 1 | 2018 | 1031 | 0.03 | Why? |
| Hospitals | 2 | 2021 | 11793 | 0.03 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.03 | Why? |
| Biomarkers | 1 | 2014 | 23361 | 0.03 | Why? |
| RNA, Messenger | 1 | 2005 | 5131 | 0.03 | Why? |
| Middle Aged | 4 | 2021 | 270681 | 0.03 | Why? |
| Pandemics | 4 | 2021 | 389249 | 0.02 | Why? |
| Male | 5 | 2021 | 367725 | 0.02 | Why? |
| ROC Curve | 1 | 2021 | 6024 | 0.02 | Why? |
| State Medicine | 1 | 2021 | 2847 | 0.02 | Why? |
| Adult | 3 | 2021 | 244371 | 0.02 | Why? |
| Apoptosis | 1 | 2017 | 2335 | 0.02 | Why? |
| Chiroptera | 1 | 2021 | 3530 | 0.02 | Why? |
| Mice, Inbred BALB C | 1 | 2017 | 5814 | 0.02 | Why? |
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2005 | 10 | 0.02 | Why? |
| Immunogenicity, Vaccine | 1 | 2021 | 4624 | 0.02 | Why? |
| Early Growth Response Protein 3 | 1 | 2004 | 3 | 0.02 | Why? |
| Disease Progression | 2 | 2020 | 13580 | 0.02 | Why? |
| Tumor Cells, Cultured | 1 | 2005 | 254 | 0.02 | Why? |
| DNA, Neoplasm | 1 | 2004 | 56 | 0.02 | Why? |
| Immunoassay | 1 | 2020 | 4485 | 0.02 | Why? |
| Intubation, Intratracheal | 1 | 2020 | 3962 | 0.02 | Why? |
| Kruppel-Like Transcription Factors | 1 | 2004 | 91 | 0.02 | Why? |
| Cell Lineage | 1 | 2005 | 241 | 0.02 | Why? |
| CpG Islands | 1 | 2005 | 230 | 0.02 | Why? |
| Bone Marrow Cells | 1 | 2005 | 186 | 0.02 | Why? |
| Gene Silencing | 1 | 2004 | 213 | 0.02 | Why? |
| Specimen Handling | 1 | 2020 | 6190 | 0.02 | Why? |
| Viral Proteins | 1 | 2020 | 7370 | 0.01 | Why? |
| DNA-Binding Proteins | 1 | 2004 | 469 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 11367 | 0.01 | Why? |
| Magnetic Resonance Imaging | 1 | 2018 | 6551 | 0.01 | Why? |
| Health Personnel | 2 | 2021 | 29646 | 0.01 | Why? |
| Sequence Deletion | 1 | 2005 | 674 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2020 | 22971 | 0.01 | Why? |
| Transcription Factors | 1 | 2004 | 784 | 0.01 | Why? |
| Gene Expression Regulation, Neoplastic | 1 | 2004 | 1014 | 0.01 | Why? |
| Acute Disease | 1 | 2005 | 6029 | 0.01 | Why? |
| Child | 1 | 2021 | 70012 | 0.01 | Why? |
| Risk Factors | 1 | 2020 | 71621 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.01 | Why? |
| Adolescent | 1 | 2021 | 86841 | 0.01 | Why? |
| Young Adult | 1 | 2021 | 93724 | 0.01 | Why? |
| Retrospective Studies | 1 | 2020 | 105322 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 13720 | 0.00 | Why? |
Mitsuya's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(242)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(176)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_